Analysts at B. Riley dropped their Q2 2025 earnings per share estimates for Denali Therapeutics in a research note issued to investors on Wednesday, March 5th. B. Riley analyst M. Mamtani now ...

Morgan Stanley analyst Sean Laaman assumed coverage of Denali Therapeutics (DNLI) with an Overweight rating and a price target of $33, down ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Denali Therapeutics (DNLI – Research Report), ...

We recently compiled a list of the Jeff Bezos Investments in 2025: 12 Companies Bezos Is Investing In. In this article, we ...

Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) hit a new 52-week low on Tuesday after Oppenheimer lowered their price target on the stock from $50.00 to $42.00. Oppenheimer currently has an ...

Denali Therapeutics DNLI reported a fourth-quarter 2024 loss of 67 cents per share, narrower than the Zacks Consensus ...

In trading on Monday, shares of Denali Therapeutics Inc (Symbol: DNLI) entered into oversold territory, hitting an RSI reading of 29.2, after changing hands as low as $15.745 per share.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...